Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × balixafortide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 284 Carboplatin 278 pembrolizumab 274 Cisplatin 234 Gemcitabine 232 Docetaxel 219 Bevacizumab 217 Nivolumab 193 Pemetrexed 173 Rituximab 160 Cyclophosphamide 153 Capecitabine 150 Dexamethasone 145 Trastuzumab 126 Fluorouracil 125 Prednisone 106 Erlotinib Hydrochloride 101 Ipilimumab 98 Oxaliplatin 97 atezolizumab 96 Sunitinib 93 Doxorubicin 90 Leucovorin 85 Cetuximab 84 Irinotecan 82 Lenalidomide 73 130-nm albumin-bound paclitaxel 73 Bortezomib 64 durvalumab 63 Azacitidine 63

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03786094 2023-11-01

FORTRESS

Spexis AG

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡